Drugs / Songling Xuemaikang Capsule
last change Jun 2026 re-read 3 minutes ago

Songling Xuemaikang Capsule

Developed for
hypertensive disorder
Investigated by
Chengdu Kanghong Pharmaceutical Co., Ltd. · Jing Liu

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
— NCT07709442 Jun 2026 → Jun 2027 expected hypertensive disorder Jing Liu Not yet recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Songling Xuemaikang Capsule ClinicalTrials.gov intervention name — accepted as the source's own label NCT07709442 ↗